New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance
详细信息 查看全文
- 作者：Ling-Shan Syuea ; Yen-Hsu Chenb ; c ; Wen-Chien Koa ; d ; winston3415@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Po-Ren Hsuehe ; hsporen@ntu.edu.tw" class="auth_mail" title="E-mail the corresponding author
- 关键词：Intra-abdominal infections ; Antimicrobial resistance ; Ceftolozane ; Avibactam ; Eravacycline ; Plazomicin
- 刊名：International Journal of Antimicrobial Agents
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：47
- 期：4
- 页码：250-258
- 全文大小：1520 K
文摘
- •
Resistance problems vary greatly worldwide in intra-abdominal infections (IAIs) and are of serious concern in the Asia-Pacific region, Latin America and the Middle East.
- •
A number of novel antibiotics, including ceftolozane/tazobactam, ceftazidime/avibactam, eravacycline and imipenem/relebactam, have completed clinical trials and were targeted at ESBL-producing and AmpC-producing pathogens.
- •
New lipoglycopeptides and oxazolidinones provide options against resistant Gram-positive pathogens for treating healthcare-associated IAIs.